The Role of Endothelin in the Supine Hypertension of Autonomic Failure

This study is currently recruiting participants.
Verified June 2013 by Vanderbilt University
Sponsor:
Information provided by (Responsible Party):
Italo Biaggioni, Vanderbilt University
ClinicalTrials.gov Identifier:
NCT01119417
First received: May 4, 2010
Last updated: June 20, 2013
Last verified: June 2013

May 4, 2010
June 20, 2013
May 2010
November 2014   (final data collection date for primary outcome measure)
Change in Systolic BP [ Time Frame: 0 -4 hr post infusion ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01119417 on ClinicalTrials.gov Archive Site
Change in cardiac output, stroke volume and systemic vascular resistance [ Time Frame: 0-4 hr post infusion ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
The Role of Endothelin in the Supine Hypertension of Autonomic Failure
The Role of Endothelin in the Supine Hypertension of Autonomic Failure

The purpose of this study is to test the hypothesis that endothelin plays a role in the pathogenesis of supine hypertension in pure autonomic failure by increasing vascular resistance. To gauge its contribution to blood pressure regulation, pure autonomic failure and multiple system atrophy patients with supine hypertension will undergo a medication testing with the endothelin blocker, BQ123. We will compare the hemodynamic effects between PAF and MSA patients. Our primary endpoint will be the decrease in blood pressure during the administration of this compound.

The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure are not completely understood.In MSA patients, supine hypertension may be explained by residual sympathetic tone, possibly acting on hypersensitive adrenoreceptors and unstrained by the lack of baroreflex modulation. In contrast, the pathogenesis of hypertension in PAF remains unknown. Hypertension in these patients is not related to intravascular volume, residual sympathetic tone, or renin mechanisms. Increased vascular resistance is the underlying hemodynamic mechanism. The driving force of this increased vascular tone, however, is not known.

We hypothesize that endothelin (ET)-l contributes to the increased vascular resistance in pure autonomic failure patients with supine hypertension. To gauge its contribution to blood pressure regulation, we will induce endothelin blockade with acute systemic administration of BQ123 in an ascending dose regimen (25, 50, 100 and 300 nmol/min) and we will compare the hemodynamic effects between PAF and MSA patients.

Subjects will be studied on 3 different days, one with saline (placebo) and two with BQ123: a 'low dose' day (25 and 50 nmol/min infusions separated by 75 min) and a 'high dose' day (100 and 300 nmol/min infusions separated by 75 min). The order of the placebo day will be randomized in a single-blinded manner so that each subject receives it on a different visit. The order of the BQ123 study days will be always the same, starting with the low dose. If SBP drops by >40 mm Hg or SBP < 130 mm Hg during the monitoring period after the first or second infusion, the following dose(s) of BQ123 will not be given and patients will receive normal saline until the study ends.

Ganglionic Blockade with Trimethaphan (optional study day):

The purpose of this study day is to determine the level of residual sympathetic tone that contributes to supine hypertension in each autonomic failure patient by inducing transient withdrawal of the autonomic nervous system. This approach would allow us to identify patients in whom supine hypertension is not driven by sympathetic tone and thus, better characterize the role of endothelin in the hypertension of these patients.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
  • Hypertension
  • Pure Autonomic Failure
  • Multiple System Atrophy
  • Drug: BQ123
    Low dose day: 25 nmol/min, single IV infusion for 15 min.
    Other Name: BQ-123 sodium salt
  • Drug: BQ123
    Low dose day: 50 nmol/min, single IV infusion for 15 min
    Other Name: BQ-123 sodium salt
  • Drug: Bq123
    High dose day: 100 nmol/min, single IV infusion for 15 min.
    Other Name: BQ-123 sodium salt
  • Drug: BQ123
    High dose day: 300 nmol/min, single IV infusion for 15 min.
    Other Name: BQ-123 sodium salt
  • Drug: Saline
    2-3 IV saline infusions for 15 min each.
    Other Name: Normal saline, 0.9% sodium chloride
  • Experimental: BQ123
    endothelin blocker
    Interventions:
    • Drug: BQ123
    • Drug: BQ123
    • Drug: Bq123
    • Drug: BQ123
  • Placebo Comparator: Saline
    IV saline
    Intervention: Drug: Saline
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
12
November 2014
November 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with autonomic failure and supine hypertension from all races, who are in the hospital participating in the study "The Evaluation and Treatment of Autonomic Failure" (IRB# 000814).
  • Supine hypertension, defined as a systolic blood pressure >150 mm Hg or diastolic blood pressure > 90 mm Hg.
  • Males and females, between 18-85yr.
  • Provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care.

Exclusion Criteria:

  • Pregnant women.
  • High-risk patients (e.g. heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction).
  • History of serious allergies or asthma.
  • In the investigator's opinion, have clinically significant abnormalities on clinical, mental examination or laboratory testing.
  • All medical students.
Both
18 Years to 85 Years
No
Contact: Bonnie K Black, R.N. 615-322-3304 adcresearch@vanderbilt.edu
United States
 
NCT01119417
091344
No
Italo Biaggioni, Vanderbilt University
Vanderbilt University
Not Provided
Principal Investigator: Italo Biaggioni, M.D. Vanderbilt University
Vanderbilt University
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP